Blog

News

Why Getting Clinical Trial Material into Europe Can Feel So Hard

2026-06-18

Share

The different regulatory philosophies behind early-phase GMP in the EU and the US and how to navigate both.

A few years ago, I found myself in conversation with another Brit as we waited to board a flight back to Heathrow. The airport was in Boston, so it was no great surprise to discover we both worked in biotech. I was there in a quality auditor capacity; they were a project manager.

 

When I mentioned I worked for the UK arm of an Italian company, they stopped me.

 

“We’ve just started Phase 1, so we don’t have to worry about Europe yet.”

 

When I asked why Europe was a worry, they weren’t sure. Not their area. So they turned the question back to me.

 

“Why is it so hard to get clinical trial material released in Europe?”

 

From their perspective, nothing had changed. The manufacturing process was the same. The product was the same. The clinical study design was the same. And yet the regulatory expectations suddenly felt entirely different.

 

This isn’t really about one system being stricter than the other. It’s about what each framework is trying to prioritise at different stages of development.

 

The EU framework emphasises • control.

The FDA framework emphasises • learning.

Both regulators are solving the same problem: ensuring clinical trial material is safe, controlled, and suitable for use in patients. They simply place the emphasis differently and for companies developing medicines across both regulatory environments, that difference shapes the entire development strategy.

 

Why the FDA model prioritises learning

The FDA framework for early clinical development is deliberately flexible. Phase 1 investigational drugs are not expected to meet the same detailed GMP requirements as commercial medicines. The focus instead is on ensuring manufacturing controls are appropriate for the stage of development, and sufficient to protect patient safety.

 

This reflects the reality of early development. Manufacturing processes are still evolving, analytical methods are still being refined, and the understanding of critical quality attributes is still developing. Requiring a fully mature GMP system at Phase 1 would slow many programmes significantly, and for advanced therapies, where the process is often the product, it simply would not be realistic.

 

For small biotech companies, academic spin-outs, and advanced therapy developers, that flexibility can be the difference between entering the clinic and getting stuck in development.

 

But flexibility carries responsibility. When requirements are less prescriptive, the burden shifts onto the sponsor to define what ‘appropriate control’ actually means. For experienced organisations, this works well. For less experienced teams, decisions can be scientifically sound but insufficiently documented, storing up problems for later.

Why the EU model prioritises control

The European framework approaches early development from a different starting point. Investigational medicinal products are expected to sit within a formal GMP structure from the outset. Product specification files, QP certification, defined batch release processes and documented quality systems are all part of the framework, even at Phase 1.

Flexibility exists. Regulators understand that early-phase processes evolve. But that flexibility exists within a structured quality system, rather than outside it.

The advantages are clear. By embedding traceability and governance early, the EU framework ensures manufacturing decisions are documented, changes are assessed, and supply chains remain transparent as programmes grow. That discipline becomes increasingly important as development expands across multiple clinical sites, manufacturing partners, and international markets.

The downside is that the system can feel heavyweight for early-stage programmes. Sponsors used to the FDA framework often find European expectations surprisingly formal, not because the requirements are unreasonable, but because the underlying philosophy is genuinely different.

Planning ahead without slowing innovation

One practical way to navigate the difference is straightforward, and it’s the approach many Arithmos clients take: develop under the FDA framework, but periodically assess the programme against European GMP expectations.

 

In other words: conduct the gap analysis early.

 

There may be no regulatory obligation to close those gaps immediately. Early development is still a time for learning and iteration. But understanding where the gaps exist gives organisations something valuable: time.

 

  • Time to strengthen documentation.
  • Time to formalise processes.
  • Time to build traceability and governance into the manufacturing system before it becomes critical.

 

Without that visibility, the pressure appears much later: when a programme is preparing to expand into Europe, when clinical timelines are tight, and when the product itself may have a limited shelf life. At that point, fixing structural GMP gaps is far harder. Manufacturing timelines shorten, supply chains grow more complex, and the margin for delay narrows, particularly when subjects are already enrolled in European studies.

 

Organisations that have already assessed themselves against EU expectations tend to know exactly what needs to change. They may not have implemented every element yet, but the roadmap is clear. This allows sponsors to move quickly under the FDA framework while preparing for European requirements in parallel.

 

The most effective strategy is rarely to choose between the FDA and EU approaches. It is to use the strengths of both.

In early development, you can buy flexibility. What you cannot buy later is time.

How Arithmos can help

Arithmos works with sponsors and CROs at every stage of clinical development. Our GMP consulting team helps clients understand the gap between where their programme is and where European regulators will expect it to be, early enough to do something about it.

 

Whether you’re preparing for first-in-human studies, planning an EU expansion, or looking to align your manufacturing quality system ahead of commercialisation, we can help you assess where you stand and build a clear path forward.

Speak to our GMP team  If you’re developing under the FDA framework and planning an EU expansion, a structured gap assessment is often the most effective first step. 

About the Author

Chris Strong
GMP Auditor

Chris Strong joined Arithmos in January 2024 as a GMP Auditor, planning and executing Good Practice audits for clients across multiple sectors, managing audit findings, and supporting quality system and business improvement initiatives.

Previously, he spent over six years as Quality Specialist at Dechra Pharmaceuticals, providing quality oversight across the contract manufacturing network, leading CMO audits, and supporting technical transfers, new product introductions, and remediation activities. Earlier roles include Quality Manager at Quality Context, where he managed GMP and ISO 9001 quality systems and delivered QMS consultancy and training, as well as positions at Church & Dwight UK, Reckitt Benckiser, and FUJIFILM Diosynth Biotechnologies.

With more than 20 years’ experience in the pharmaceutical and life sciences industries, Chris specialises in GMP compliance, contract manufacturing quality, and audit management. At Arithmos, he leads auditing and quality assurance services including site audits, risk assessments, batch record reviews, QMS improvements, and gap analysis.

About Arithmos

With deep expertise in the Life Science Industry, Arithmos supports companies in their digital transformation journey to achieve the best value from technology-enabled solutions and excellence in business operations.

Arithmos team share extensive knowledge of the full GxP regulated environment for both deliveries of services and technologies, and our domains range from Clinical Development, Quality & Compliance, Pharmacovigilance & Safety and, Regulatory Affairs.

Get an assessment

Contact us now to receive further information and an assessment from our experts. We will work with you to evaluate the best approach for your business processes.

From our resources